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Purpose: We report the clinical course and visual outcome of patients with diabetes mellitus (DM) who subsequently
developed uveitis from any cause.
Methods: Longitudinal, retrospective case note review.
Results: A total of 36 patients (M/F: 18/18, 58 eyes) were included, Of the 36 patients, 35 had Type 2 DM and one had
Type 1 DM. Mean age of onset of DM was 49 years and uveitis 55 years. The uveitis was bilateral in 22 (61%) patients.
There were 19 patients with anterior uveitis, 12 with panuveitis and 5 with intermediate uveitis. Mean follow up was
4.4 years (range 1-18). Mean number of uveitis recurrences was 3 (range 1-7). Causes of vision of 6/18 or worse appeared
related to the uveitis in 9 eyes and diabetes in 4 eyes. Cataract occurred in 22 eyes, glaucoma in 17 eyes, and cystoid
macular oedema in 10 eyes. Diabetic retinopathy was detected in 38 (65.5%) eyes (29 non-proliferative including 6 with
clinically significant macular oedema, and 9 proliferative). Progression of diabetic retinopathy to proliferative stage
occurred in 7 eyes of 4 patients over a mean duration of 4.4 years. In 10 patients with active uveitis the mean HbA1c
was 80 mmol/mol [9.5%], (range 49-137 [6.6-14.7]), and 67 mmol/mol [8.3%] (range 46-105 [6.4-11.8]) when the uveitis
was quiescent, p = 0.01. Better glycaemic control was required in 10 patients during episodes of uveitis.
Conclusions: Patients with DM who develop uveitis may have a high complication rate, reduced vision and poor
glycaemic control. Checking blood glucose during episodes of uveitis is important.
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Diabetic retinopathy is the third commonest cause of
blindness in the Western world, with a 20% preva-
lence of blindness in the middle age group [1]. The
incidence of diabetes mellitus (DM) is increasing rap-
idly in developed nations, and in the UK the number of
people diagnosed has increased from 1.4 to 2.6 million
since 1996 [2].
Uveitis and DM are individually potential sight threaten-
ing conditions. Uveitis may be idiopathic, associated with a
range of systemic diseases, or caused by an infectious agent
leading to variable intervals and degrees of vision impair-
ment [3]. It is the fifth commonest cause of blindness in
the middle age group with a prevalence of 10% in the de-
veloped world [1]. As both DM and uveitis predominantly* Correspondence: p.i.murray@bham.ac.uk
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reproduction in any medium, provided the oroccur in patients of working age, vision loss can have a
major socioeconomic impact.
To our knowledge there is no study describing the clin-
ical course of the diabetes and DM related eye changes in
patients who develop uveitis with pre-existing DM. As
both uveitis and DM disrupt blood-ocular barriers, we
also wished to know the visual impact of these co-
existing conditions. We acknowledge the limitations of
the study as there was no control group and not all pa-
tients had HbA1C values.Patients and methods
This was a retrospective, longitudinal, case note study
of patients attending the specialist Uveitis clinics at the
Birmingham and Midland Eye Centre, a tertiary referral
centre in the United Kingdom. Patients presenting with
their first attack of uveitis from any cause who had pre-
existing DM were included. Where appropriate, patients
were investigated for any underlying systemic disease ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.










Mean age of onset (years) 55
Laterality 14 unilateral, 22 bilateral
Anterior 32 eyes (19 patients)
Panuveitis 19 eyes (12 patients)
Intermediate 7 eyes (5 patients)
Diabetes
Mean age of onset (years) 49
Type 1 1
Type 2 35
Table 2 Uveitis disease associations/syndromes
Clinical classification Diagnosis Number of eyes
(patients)
Infectious Tuberculosis 4 (2)
Syphilis 1 (1)
Toxoplasmosis 1 (1)
Non-infectious Sarcoidosis 4 (2)
Fuchs’ heterochromic cyclitis 3 (3)
HLA-B27 related 2 (2)
Presumed diabetes mellitus 6 (4)
Idiopathic 37 (21)
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with full blood count, erythrocyte sedimentation rate,
urea and electrolytes, liver function tests, C-reactive pro-
tein, angiotensin converting enzyme, anti-nuclear anti-
body, anti-neutrophil cytoplasmic antibody, syphilis
serology and a chest x-ray. Additional investigations,
such as toxoplasma antibodies and Mantoux test were
undertaken where clinically indicated. Classification and
grading of uveitis was undertaken according to the
Standardization of Uveitis Nomenclature (SUN) Working
Group classification [4]. The clinical course of the uveitis,
frequency of recurrence and treatment undertaken were
documented. The type of DM, DM treatment, changes in
the DM treatment, types of diabetic retinopathy and
maculopathy and its course and treatment were noted.
Visual acuities and causes for poor vision were recorded.
Where available HbA1c values throughout the clinical
course were documented and compared with either ac-
tive or quiescent uveitis.
Results
A total of 58 eyes of 36 patients were included. Apart
from 1 patient who was diagnosed with DM at presen-
tation and had bilateral fibrinous uveitis and prolifera-
tive diabetic retinopathy all other patients were known
to have pre-existing DM. The mean age (±SD) at the
onset of DM was 48.6 (±13.9) years (range: 8-78 years),
and the age at onset of uveitis was 55.4(±13.9) years
(range: 33-82 years). The mean period (±SD) between
the onset of DM and uveitis was 6.8 (±8.3) years (range:
0-31 years). The mean (±SD) follow up period was 4.4
(±4.5) years (range: 1-18 years). There was an equal
gender distribution; 17 patients were South Asian, 10
Caucasian and 9 African-Caribbean. The uveitis was bi-
lateral in 22 patients and unilateral in 14 patients.
There were 35 patients with Type 2 DM and 1 with
Type 1 DM. Diabetic treatment at first presentation
with uveitis comprised diet alone in 2 patients, oral
hypoglycaemic agents (OHA) in 21 patients, and insulin
in 13 patients (demographic data is summarised in
Table 1). Impairment of glycaemic control had occurred
in 10 patients with uveitis. 2 patients on diet control
were started on OHAs, 2 patients on OHA had another
agent added to their treatment, 1 patient who had
stopped using OHA had to be restarted on it, 2 patients
on OHA had to be started on insulin and 3 patients on
insulin had to have their insulin dose increased to
achieve better glycaemic control.
The anatomical type of uveitis was anterior in 32 eyes
(19 patients), panuveitis in 19 eyes (12 patients), and
intermediate in 7 eyes (5 patients). No patient had pos-
terior uveitis. There were 32 patients (52 eyes) with
non-infectious uveitis, and 4 patients (6 eyes) with an in-
fectious cause. Of these 32 patients, 3 patients (3 eyes)had Fuchs’ heterochromic cyclitis, 2 patients (4 eyes) had
sarcoidosis, and 2 patients (2 eyes) had HLA-B27 related
uveitis. In 4 patients (6 eyes), it was presumed that the
uveitis was a direct result of uncontrolled DM. These pa-
tients presented with severe uveitis, had high glycosylated
haemoglobin, while other investigations to establish sys-
temic associations were negative. Over the follow-up
period, better glycaemic control was associated with
improvement/resolution of the uveitis. The infectious
causes in this cohort of patients were tuberculosis 2 pa-
tients (4 eyes), syphilis 1 patient (1 eye) and toxoplasma
1 patient (1 eye). Uveitis was acute in 14 patients, recur-
rent in 10 patients and chronic in 12 patients. The type
of uveitis, disease association/syndromes are shown in
Table 2.
Presenting Snellen visual acuity was 6/12 or better in
26 eyes (45%), 6/18-6/60 in 19 eyes (33%) and worse
than 6/60 in 13 (22%) eyes. Anterior chamber (AC)
showed 3-4+ cellular reaction in 17 eyes (29%), 3-4+ flare
Table 3 HbA1c levels in active and quiescent periods of
uveitis in 10 patients
HbA1c levels in active period
IFCC units - mmol/mol
(DCCT units - %)
HbA1c levels in quiescent period
IFCC units - mmol/mol
(DCCT units - %)
110 (12.2) 78 (9.3)
137 (14.7) 105 (11.8)
60 (7.6) 62 (7.8)
65 (8.06) 61 (7.75)
70 (8.6) 54 (7.1)
49 (6.6) 46 (6.4)
61 (7.7) 63 (7.9)
95 (10.8) 79 (9.4)
81 (9.6) 63 (7.9)
75 (9.0) 62 (7.8)
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hypopyon in 3 eyes (5.2%). Macular status could not be
assessed at presentation in some patients due to hazy
media such as corneal oedema, small pupil, fibrin, cata-
ract and vitreous haze.
The average number (±SD) of uveitic episodes in these
patients was 3 (±2.2), range: 1-7 over the follow-up
period. Cataract of varying degrees was seen in 22 eyes
of 15 patients, posterior synechiae in 29 eyes, cystoid
macular oedema (CMO) was present in 10 eyes of 8 pa-
tients. Raised intraocular pressure (IOP) requiring treat-
ment was found in 17 eyes of 11 patients. One eye (one
patient) developed iris bombé. Uveal effusion was noted in
1 eye that resolved with an improvement in the uveitis.
Diabetic retinopathy was noted in 38 eyes of 24 pa-
tients. Non-proliferative diabetic retinopathy was seen in
29 eyes of 19 patients. Proliferative diabetic retinopathy
was seen in 9 eyes of 5 patients including vitreous haem-
orrhage in 3 eyes. All 9 eyes underwent panretinal laser
photocoagulation. Apart from 1 patient who developed
asymmetric diabetic retinopathy all other 23 patients had
symmetric diabetic retinopathy. The patient with asym-
metric diabetic retinopathy presented with unilateral
panuveitis. Over 3 months the uveitic eye progressed to
proliferative diabetic retinopathy while the non-uveitic
eye remained at the non-proliferative stage. Clinically
significant macular oedema developed in 6 eyes of 5
patients. These patients had non-proliferative diabetic
retinopathy and received macular laser treatment.
Fluorescein angiography and optical coherence tom-
ography were not undertaken on a routine basis and
was only available for some of the patients where clin-
ically indicated such as in macular oedema. Some of
the patients were seen in the period in which OCT
was not routinely undertaken.
After a mean follow up period of 4.4 years, progression
from non-proliferative to proliferative stage was noted in
7/38 (18.4%) eyes (4/24 patients, 16.7%) with diabetic
retinopathy.
All patients received topical steroids and a dilating
agent during the uveitic episode. Throughout the follow
up period regional corticosteroid injections were re-
quired in 10 eyes (9 patients). Pulsed intravenous meth-
ylprednisolone (1 g/kg per day for 3 days) was given to
1 patient, 9 patients received systemic corticosteroids
and 2 patients received systemic immunosuppressive drugs
(1 azathioprine, 1 cyclosporine). Of these 9 patients who
received systemic corticosteroids only 1 patient on long
term 5 mg oral prednisolone had progression of non-
proliferative to proliferative DR and 2 patients on short
course of systemic corticosteroids needed better gly-
caemic control. In the patients with an infectious aeti-
ology, 1 patient received a systemic anti-parasitic agent
for clinically presumed toxoplasma uveitis, both patientswith pulmonary tuberculosis were started on anti-
tuberculosis therapy, and the patient with syphilis re-
ceived intramuscular penicillin.
In those patients needing treatment for raised intraocular
pressure, 1 patient (2 eyes) was given intravenous and oral
acetazolamide with topical anti-glaucoma medications, and
10 patients (15 eyes) received only topical anti-glaucoma
medications. Cataract surgery was performed in 19 eyes
(13 patients), diagnostic vitreous biopsy was undertaken in
1 eye (1 patient), 2 eyes (2 patients) had vitrectomy for vit-
reous haemorrhage secondary to proliferative diabetic ret-
inopathy, and 1 eye (1 patient) with iris bombé had a
surgical peripheral iridectomy followed by trabeculectomy
at a later stage for uncontrolled IOP.
HbA1c values were available in 10 patients during both
active inflammatory stage and during the quiescent period
(Table 3). The mean (±SD) HbA1c of 80 mmol/mol [9.5%]
(±27 [2.4]) during active uveitis was statistically signifi-
cantly higher than the mean (±SD) HbA1c of 67 mmol/
mol [8.3%] (±27 [2.4]) during inactive uveitis, p = 0.01
(paired t-test). During the course of uveitis serial HbA1c
values were available in 18 patients in the active period
and in 20 patients in the quiescent period. Active period
mean (±SD) was 75 mmol/mol [9.0%] (±26 [2.3]) and
quiescent period mean (±SD) value was 61 mmol/mol
[7.7%] (±16 [1.5]).
Figure 1 shows a Kaplan Meier survival curve for eyes
with vision of better than 6/18. A visual acuity of 6/18 or
worse was documented in 17 eyes (29%) of 15 patients.
This was considered uveitis related in 9 eyes (9 patients).
Persistent CMO was seen in 4 eyes (4 patients). The
patients who had persistent CMO did not have any
evidence of diabetic retinopathy; hence it was thought
to be due to uveitis. Three eyes (3 patients) had macu-
lar epiretinal membrane/scar, 1 eye had vitreous debris
and 1 eye had persistent vitreous inflammation. Poor
vision appeared diabetic retinopathy related in 4 eyes
Figure 1 Kaplan-Meier survival curve for eyes with vision better than 6/18.
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maculopathy and in 1 eye was due to vitreous haemor-
rhage. Other causes of poor vision in this group of
patients was central retinal vein occlusion in 1 eye, ad-
vanced cataract and glaucoma in in each eye of 1 patient
who refused treatment for both these conditions, and age
related macular degeneration in 1 eye. The causes of re-
duced vision are summarised in Table 4.
Discussion
This longitudinal study aimed to investigate the clinical
course when uveitis from any cause and DM has
coexisted and its impact on visual outcome. It was not
our aim to compare uveitis patients with and without
DM. We also wished to know if uveitis had any bearing
on blood sugar control. The relationship between DM
and uveitis has been proposed by a number of reports
[5-10] but to our knowledge this is the first study in a
cohort of patients with DM in whom the clinical courseTable 4 Causes of reduced vision
Uveitis related Number of eyes (patients)
Persistent CMO 4 (4)
Macular scar/ERM 3 (3)
Vitreous debris/inflammation 2 (2)
Diabetic retinopathy related
Maculopathy 3 (2)
Vitreous haemorrhage 1 (1)
Others
CRVO 1 (1)
Cataract with glaucoma 2 (1)
AMD 1 (1)
CMO Cystoid Macular Oedema, ERM Epiretinal Membrane, CRVO Central
Retinal Vein Occlusion.of uveitis, relationship to blood sugar control, progres-
sion of diabetic retinopathy and visual outcome have
been studied.
Blindness due to diabetic retinopathy and uveitis are
both potentially treatable and among the top five
commonest causes of blindness in the middle-aged
population [1]. In our cohort of middle-aged patients
42% (15 patients, 17 eyes) had final visual acuity worse
than 6/18. In 9 eyes (53%) the poor visual acuity was
thought to be uveitis related, with four of these eyes having
persistent CMO. Coexistence of these two conditions ap-
pears to have a higher rate of poor visual acuity.
Interestingly the majority of our cohort (26 patients,
72%) were from ethnic minorities (South Asian and
African-Caribbean origin) that probably reflects the
population served by the Birmingham and Midland Eye
Centre although it appears much higher than the average
population of ethnic minorities of 29.6% in Birmingham
compared to 9.1% in England as per the 2001 census.
There is recent evidence suggestive of a high prevalence of
DM in ethnic minorities in the UK [11] that may contrib-
ute to the increased number of this cohort of patients in
our study.
We have previously published the presenting features
of uveitis in most of these patients [12]. Our study sug-
gests that patients with pre-existing DM presenting with
uveitis may exhibit increased intraocular inflammation
that does not appear to be related to the type of uveitis
and subsequently had on average three recurrences.
There was evidence of high degrees of AC flare, dense fi-
brin and cellular reaction. This severe fibrinous reaction
was likely to be responsible for the large number of eyes
with posterior synechiae (50%) and the eyes with raised
IOP (29%). In four patients the uveitis was likely to be
related to DM as investigations failed to reveal any
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caemic control, and all had a severe fibrinous reaction in
the AC in line with previous reports [5-10,12]. It is inter-
esting that severe inflammation was also noted in the
eyes where DM was not suspected as a cause of the uve-
itis. It is likely that the severe inflammation was related
to the additional blood-ocular barrier breakdown and/or
ocular ischaemia from pre-existing DM, particularly as
there was mean of almost seven years between diagnosis
of DM and onset of uveitis, and some patients already
had evidence of diabetic retinopathy.
Cataract has been reported as a cause of visual loss in
17.7% of patients with uveitis [3]. DM has been impli-
cated as a risk factor in the causation of cataract [13-15].
Our cohort had high incidence of cataract (38%) that
may be due to a combination of uveitis and DM. During
the course of uveitis 12 patients (33%) needed systemic/
regional corticosteroids and/or immunosuppressive agents
to gain control of inflammation. This highlights the se-
verity of inflammation and the requirement to intervene
with second or third line treatment strategies to achieve
control of the inflammation.
In a study of over 10,000 patients with DM in the UK
the prevalence of diabetic retinopathy has been reported
to be 16.5% [16,17]. Our cohort had diabetic retinopathy
in 24 patients (66.7%), which is four times higher. The
UK Prospective Diabetes Study showed that people with
improved glucose control reduced the requirement of
laser treatment of the eye by a quarter [18]. Progression
of diabetic retinopathy to the proliferative stage over a
4-year follow up in WESDR study in 1075 patients was
reported to be 4.7% [19]. In our study 18.4% of patients
went on to develop proliferative diabetic retinopathy
over an average of 4.36 years. The co-existing uveitis
could trigger mechanisms for progression of diabetic
retinopathy amongst other factors. However we were
unable to identify other main risk factors, such as
hypertension and hyperlipidaemia to have a contribu-
tory role in our cohort. It was interesting to note rapid
progression of non-proliferative diabetic retinopathy to
proliferative in one eye of a patient with panuveitis in
that eye. There are a number of reports in the litera-
ture suggesting either a causative or a protective role
of uveitis in relation to proliferative diabetic retinop-
athy [20-23]. In the current literature 6 uveitic eyes
progressed to PDR in patients with DM whereas two eyes
did not progress. This suggests a possible role of worsen-
ing diabetic retinopathy in patients with uveitis.
We have previously shown that HbA1c is raised in DM
patients at presentation with uveitis [12]. We attempted
to correlate glycaemic control with episodes of uveitis.
HbA1c values were available in 10 patients during the ac-
tive uveitic phase as well as in the quiescent phase. All
patients had a value higher than the recommended44 mmol/mol (6.2%) in the active phase as compared
to the quiescent phase that was statistically signifi-
cant. This suggests that poor glycaemic control may
be a trigger for the reactivation of the uveitis. Over-
all, HbA1c values were available in 18 patients during the
active phase and in 20 patients in the inactive phase. The
mean value during the active phase was much higher than
the quiescent phase. A limitation of this study is its retro-
spective nature and regular glycosylated haemoglobin
values were not available in all patients.
During the course of uveitis 10 patients needed a
change in their DM treatment to gain better glycaemic
control that was thought to help in control of the in-
flammation. This highlights the need to check the blood
glucose levels and HbA1c levels in patients with DM
who get uveitis, irrespective of aetiology. Treatment with
systemic corticosteroid therapy can influence the gly-
caemic control. Only one of these patients was on low
dose of 5 mg oral prednisolone and 2 received short
course of systemic steroids. They all required multidis-
ciplinary input to gain better blood sugar control.
Stabilization of blood sugars seemed to help in control-
ling the inflammation.
Conclusions
Uveitis occurring in patients with pre-existing diabetes
can be associated with numerous ocular complications
and recurrences. Macular involvement related to both
the uveitis and the diabetes appears to be the main cause
of reduced vision. Better control of DM with treatment
may result in better control of inflammation as seen in
some of our patients. Where uveitis and diabetes co-
exist, ophthalmologists and diabetic physicians should
be aware that glycaemic control might not be optimal.
Monitoring glycaemic control in all diabetics presenting
with uveitis should be mandatory.
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